Problem: The immune system normally exists in a balanced state, but in the case of autoimmune disease, this balance is askew, and the therapeutic effort required to rebalance it can be complex.
Solution: Pandion’s technology is designed to create a suite of therapies for rebalancing the immune system.
What Makes us Different?
Pandion’s approach to developing modular proteins, antibodies and bispecifics starts with cutting-edge immunomodulators that work systemically by activating regulatory pathways of the immune system that suppress uncontrolled autoimmune responses. We then combine these immunomodulators with tissue-selective tethers, building modular proteins and antibodies that target the precise location within the organ to deliver the desired effect.
For the effectors – the component of our molecules that deliver the biologic effect – we have focused initially on T cell modulators. With this design, we are developing biologics that engage pathways that activate regulatory T cells (Treg) or inhibit overactive pathogenic T cells. Recent discovery efforts have expanded our effector technology to include broad-acting pathway modulators which will permit us to modulate multiple cell types with a single mechanism in a tissue-targeted manner.
Our modular approach can include the addition of tissue-selective tethers to our immunomodulators, enabling the selective targeting of distinct cellular locations within a given tissue. With tissue-selective tethers, we can fine tune the delivery of our potent immunomodulators to exactly the place where they can provide most therapeutic benefit.
Our modular proteins and antibodies are uniquely designed address specific disease mechanisms and ensure manufacturability at the outset.
We use a combination of functional screening and structural modeling to advance candidates with the right biological properties and manufacturability.
By bringing deep insights into the complex mechanisms underlying the immune pathways we wish to modulate, the Pandion team can exploit customized primary cell assays to our advantage and identify new biomarkers that accurately reflect the pharmacodynamic effects of our therapeutics.
For the effector component of the therapeutics we consider the impact of valency on eliciting agonism by receptor clustering. We also consider the impact of geometry on function of geometry or spatial constraints imposed by effector moiety format (Fab vs scFv), domain placement, and isotype. For the tether component of the molecule, functional screens play an important role in ensuring no unwanted biology arises as a result of tether target engagement. Early bispecific leads undergo configuration scanning to evaluate different component placements, format, and linker configurations.
Manufacturability assessments are conducted at each stage of the discovery process to ensure only the most robust components advance in the screening cascade. This helps us understand and mitigate risks before our molecules progress into CMC. Special emphasis is placed on generating modular proteins with highly desirable drug-like properties for each effector and tissue tether pair to ensure a seamless transition from drug discovery into drug development.